TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02003651

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quick Defense
Description: Echinacea product from Gaia Herbs.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01477892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose remifentanil
Description: non-inferiority test for low dose remifentanil 0.1mcg/kg/min compared with high dose remifentanil 0.25mcg/kg/min in pain control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose remifentanil
Description: non-inferiority test for low dose remifentanil 0.1mcg/kg/min compared with high dose remifentanil 0.25mcg/kg/min in pain control
Study: NCT04279561

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo 68Ga-PSMA-11 PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 68Ga-PSMA-11 PET/CT
Study: NCT03259334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontamalimab
Description: Participants will receive 1 mL of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontamalimab
Description: Participants will receive 1 mL of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 1 mL of sterile aqueous buffered solution.
Study: NCT00767780

Intervention type: DEVICE
Intervention: APOS biomechanical gait system
Description: a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
Study: NCT01724736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
Study: NCT04159155

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation - no drugs
Description: Observation
Study: NCT01724736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NM504:
Description: Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NM504:
Description: Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
Study: NCT02352051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: the drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
Study: NCT02983214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Study: NCT02735187

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue light treatment
Description: Phototherapy of localized psoriasis vulgaris plaque with a wearable device emitting blue light at 453nm.
Study: NCT02352051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate
Description: the drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg
Study: NCT02021058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Formula
Description: Experimental formula
Study: NCT00767780

Intervention type: DEVICE
Intervention: APOS biomechanical gait system
Description: a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase

Intervention type: DEVICE
Intervention: APOS biomechanical gait system
Description: a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
Study: NCT02021058

Intervention type: OTHER
Group type: OTHER
Intervention: Standard control formula
Description: Standard Infant formula
Study: NCT02735187

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue light treatment
Description: Phototherapy of localized psoriasis vulgaris plaque with a wearable device emitting blue light at 453nm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Treatment of contralateral localized psoriasis vulgaris plaque with Vitamin D creme (Daivonex)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Treatment of contralateral localized psoriasis vulgaris plaque with Vitamin D creme (Daivonex)
Study: NCT01007708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-108
Description: Topical application once a day for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical application once a day for 48 weeks
Study: NCT00603538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871 + carboplatin + paclitaxel
Description: Chemotherapy (carboplatin and paclitaxel) and CP-751,871 (6, 10 or 20mg/kg) will be administered by intravenous infusion every three weeks.
Study: NCT00608933

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.

Intervention type: OTHER
Group type: OTHER
Intervention: educational intervention
Description: Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
Study: NCT04032496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contemplative-Based Intervention for People Living with SLE
Description: Intervention sessions will follow a 6-week format consisting of weekly in-person sessions as well as guided homework to encourage practice at home. Some mindfulness practices that will be included are meditation, group exercise (yoga), group discussions, and deep breathing. Both participants diagnosed with SLE as well as caregivers will participate in the intervention sessions. 5 sessions will be approximately 2 hours long, while the final session will be approximately 4 hours long. Each intervention group will include approximately 4 participants with SLE and 4 caregivers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program (HEP)
Description: The HEP was designed to create an active control for mindfulness-based stress reduction (MBSR) interventions. The structure of this intervention will mirror that of the other arm of this study, but will lack the mindfulness component. The HEP includes topics such as physical activity, functional movement, music therapy, and nutrition education.
Study: NCT03435991

Intervention type: OTHER
Intervention: Validation Experience Sampling Method 'Uromate'
Description: In a period of 7 days, participants will fill out an electronic ESM assessment at 10 random moments during the day. Moreover, they will fill out a sensation-related bladder diary (SR-BD) during the last three consecutive days of filling out the ESM and several symptom questionnaires at the end of the study period.

Intervention type: OTHER
Intervention: Validation Experience Sampling Method 'Uromate'
Description: In a period of 7 days, participants will fill out an electronic ESM assessment at 10 random moments during the day. Moreover, they will fill out a sensation-related bladder diary (SR-BD) during the last three consecutive days of filling out the ESM and several symptom questionnaires at the end of the study period.
Study: NCT03182205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IME
Description: The IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets. Inspiratory load will be set at 40% of maximum static inspiratory pressure. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a clip nasal.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham IME
Description: The Sham IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets, but without a load generating resistance. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a nasal clip.
Study: NCT02417870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Study: NCT01825590

Intervention type: OTHER
Intervention: Dialysate and serum sodium concentration aligned
Study: NCT03041116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmetpantotenate
Description: Daily dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dosing
Study: NCT00833248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 3. The second and third doses of goserelin were administered on Days 31 and 59, respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
Study: NCT03393052

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Angiography
Description: Comparison of left radial versus femoral access during coronary angiography of patients who have undergone coronary artery bypass grafting surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Angiography
Description: Comparison of left radial versus femoral access during coronary angiography of patients who have undergone coronary artery bypass grafting surgery
Study: NCT02706392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02344628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Comparison of two different dosing strategies for the treatment of yaws

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Comparison of two different dosing strategies for the treatment of yaws
Study: NCT03363048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restricted
Description: Certain foods and beverages are not allowed to be purchased with food benefit dollars.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restriction plus Incentive
Description: Certain foods and beverages are not allowed to be purchased with food benefit dollars; 30% of the total dollars spent toward the purchase of certain foods result are added to their food benefit dollars.
Study: NCT04397406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levobupivacaine
Description: The patients will receive 15 ml of 0.125% levobupivacaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Description: The patients will receive 15 ml of 0.125% levobupivacaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Description: The patients will receive 15 ml of 0.125% levobupivacaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The patients will receive 13 ml of 0.125% levobupivacaine and 0.5μg/kg dexmedetomidine diluted in 2 ml saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: The patients will receive 13 ml of 0.125% levobupivacaine and 25μg fentanyl diluted in 2 ml saline.
Study: NCT02674581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral BMS-663068 (pro-drug)
Description: Oral BMS-663068 (pro-drug), metabolized to active BMS-626529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral BMS-663068 (pro-drug)
Description: Oral BMS-663068 (pro-drug), metabolized to active BMS-626529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral BMS-663068 (pro-drug)
Description: Oral BMS-663068 (pro-drug), metabolized to active BMS-626529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral BMS-663068 (pro-drug)
Description: Oral BMS-663068 (pro-drug), metabolized to active BMS-626529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral BMS-663068 (pro-drug)
Description: Oral BMS-663068 (pro-drug), metabolized to active BMS-626529
Study: NCT00332514

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: telephone call by a pharmacist
Study: NCT00909142

Intervention type: DRUG
Intervention: Bonefos (Clodronate, BAY94-8393)
Description: Patients in regular clinical practice receiving Bonefos according to local drug information
Study: NCT01619384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: An 8-week validated stress reduction program, designed to teach mindfulness.
Study: NCT02805868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Given IV
Study: NCT04009096

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 PvDBP and MVA PvDBP
Description: one dose of 5 x 10\^10 vp ChAd63 PvDBP and one dose of 2 x 10\^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 PvDBP and MVA PvDBP
Description: one dose of 5 x 10\^10 vp ChAd63 PvDBP and one dose of 2 x 10\^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 PvDBP and MVA PvDBP
Description: one dose of 5 x 10\^10 vp ChAd63 PvDBP and one dose of 2 x 10\^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen.
Study: NCT03747835

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure and Response Prevention
Description: Exposure and Response Prevention involves collaboratively developing a list of food-related fears with the patient and planning treatment sessions in which the patient is exposed to the fear and inhibits safety behaviors. The explicit goal of these exposure sessions will be to violate the patient's expectation regarding the feared stimulus, rather than to reduce fear.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Motivational interviewing techniques including reflective listening to demonstrate empathy and understanding, asking questions to elicit change talk (speech that is pro-change), evaluating the decisional balance, and managing or rolling with resistance will be incorporated throughout the treatment sessions.
Study: NCT02916498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System
Description: Spinal cord stimulation for the management of chronic neuropathic pain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System
Description: Spinal cord stimulation for the management of chronic neuropathic pain
Study: NCT00107770

Intervention type: DRUG
Group type: OTHER
Intervention: sodium phenylbutyrate
Description: histone deacteylase inhibitor
Study: NCT02293954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging
Description: Given copper Cu 64 anti-CEA monoclonal antibody M5A IV
Study: NCT02706392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROR1 CAR-specific Autologous T-Lymphocytes
Description: Given IV
Study: NCT00619866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet administered orally
Study: NCT01436227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study: NCT01241123

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulation regimen
Description: Assistance and encouragement for at least ambulation 3 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitz-Markers
Description: radiopaque markers to subjectively follow the return of bowel function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitz-Markers
Description: radiopaque markers to subjectively follow the return of bowel function

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Daily abdominal x-rays
Description: daily abdominal x-rays for 7 days - to follow the radiopaque markers

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Daily abdominal x-rays
Description: daily abdominal x-rays for 7 days - to follow the radiopaque markers
Study: NCT02293954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu 64 anti-CEA monoclonal antibody M5A IV
Description: Cu 64 anti-CEA monoclonal antibody M5A IV
Study: NCT01241123

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: pedometers
Description: to record the amount of ambulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pedometers
Description: to record the amount of ambulation
Study: NCT02221440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low flow nasal oxygen
Description: Oxygen will be administered by nasal catheter at a flow rate of 2 L/min. The therapy will continue until after delivery

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low flow room air
Description: Sham: oxygen will be administered by nasal catheter at a flow rate of 0 L/min.
Study: NCT03627598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: patients will receive high flow warmed air with low inspired fraction of oxygen between non invasive ventilation sessions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard
Description: patients will receive low flow oxygen therapy at 1 to 4 liters per minute
Study: NCT03858127

Intervention type: OTHER
Intervention: Collection of urine sample
Description: Collection of urine sample for measurement of LH and FSH

Intervention type: OTHER
Intervention: Examination of genitalia
Description: Examination of genitalia

Intervention type: OTHER
Intervention: Video messaging
Description: Short video of infant recorded at home by the parents
Study: NCT02710032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network-Based Adherence Intervention
Description: Participants in clusters randomized to the intervention arm will be asked to attend a series of weekly group workshops emphasizing a collective approach to HIV prevention and mutual support for PrEP adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Platform
Description: ii) Social Media Platform: The social media component of the intervention will include structured internet platforms designed to educate, motivate, and promote discussions of PrEP adherence within the participant network, unstructured participant-generated interactions to articulate and reinforce newly developed social norms within the network, and practical tools to support daily PrEP adherence.